Biotech Growth Trust invests in biotechnology companies worldwide, with the aim of delivering long-term capital growth. Managed by OrbiMed, the trust focuses on businesses developing new medicines and healthcare technologies with clear scientific, regulatory or commercial potential.
Portfolio manager Geoff Hsu has managed the trust since 2005. His approach is centred on finding companies with strong science, capable management and identifiable events that could increase value.
The current opportunity in biotechnology is supported by several factors. Innovation remains strong, valuations in parts of the market are considered attractive, and the US regulatory environment has been favourable towards new drug approvals. Merger and acquisition activity is also providing support.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
